Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5598 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GPX4-IN-3
CAS:<p>GPX4-IN-3 (26a) is a potent GPX4 inhibitor, inducing selective ferroptosis with 71.7% inhibition at 1 μM.</p>Fórmula:C29H24ClN3O3SCor e Forma:SolidPeso molecular:530.04VEGFR-IN-3
CAS:<p>VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.</p>Fórmula:C27H28N2O6Cor e Forma:SolidPeso molecular:476.52GGTI-2154 hydrochloride
CAS:<p>GGTI-2154 hydrochloride: selective GGTase I inhibitor, IC50 21 nM, used in cancer research.</p>Fórmula:C24H29ClN4O3Cor e Forma:SolidPeso molecular:456.97eIF4A3-IN-6
CAS:<p>eIF4A3-IN-6 is a potent eIF4A inhibitor, potentially used for treating eIF4A-related diseases like cancer. (US20170145026A1)</p>Fórmula:C26H25N3O5Cor e Forma:SolidPeso molecular:459.49Murizatoclax
CAS:<p>AMG 397 is an oral MCL1 inhibitor .</p>Fórmula:C42H57ClN4O5SPureza:98%Cor e Forma:SolidPeso molecular:765.44Tofacitinib Prodrug-1
<p>Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.</p>Fórmula:C36H39ClN10O7Cor e Forma:SolidPeso molecular:759.21DC-U4106
CAS:<p>DC-U4106: USP8 inhibitor, Kd 4.7μM, IC50 1.2μM, degrades Erα, low-toxicity tumor suppressor for breast cancer research.</p>Fórmula:C29H27N5O5Cor e Forma:SolidPeso molecular:525.56KDM1/CDK1-IN-1
<p>KDM1/CDK1-IN-1 inhibits KDM1 (IC50: 0.096 μM) & CDK1 (IC50: 0.078 μM), blocks HOP-92 G2/M phase, induces apoptosis, toxic to cancer cells.</p>Fórmula:C22H17N5O3SCor e Forma:SolidPeso molecular:431.47HER2-IN-10
<p>HER2-IN-10 is a psoralen derivative that induces apoptosis. HER2-IN-10 shows anti-breast cancer activity and light-activated cytotoxicity [1].</p>Fórmula:C15H13NO5Cor e Forma:SolidPeso molecular:287.27Tubulin polymerization-IN-4
CAS:<p>Tubulin polymerization-IN-4: inhibits tubulin (IC50=4.6 μM), blocks G2/M phase, induces apoptosis, hinders cell cloning/migration, damages vasculature.</p>Fórmula:C21H21ClN2O4Cor e Forma:SolidPeso molecular:400.86YK5
CAS:<p>YK5 is an allosteric inhibitor pocket of Hsp70 and represents a previously unknown chemical tool to investigate cellular mechanisms associated with Hsp70.</p>Fórmula:C18H24N8O3SPureza:98%Cor e Forma:SolidPeso molecular:432.50KIRA9
<p>KIRA9 inhibits IRE1 with a 4.8 μM IC50, blocking ER-stress-induced mRNA decay and apoptosis by fully binding IRE1's ATP site.</p>Fórmula:C27H27F3N6O3SCor e Forma:SolidPeso molecular:572.6Fluvastatin sodium monohydrate
CAS:<p>Fluvastatin (XU 62-320) sodium monohydrate, a fully synthetic competitive HMG-CoA reductase inhibitor, features an IC 50 of 8 nM. This compound also safeguards vascular smooth muscle cells from oxidative stress via the Nrf2-dependent antioxidant pathway [1] [2].</p>Fórmula:C24H27FNNaO5Cor e Forma:SolidPeso molecular:451.46Akt/NF-κB/JNK-IN-1
<p>Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signalling pathways.Akt/NF-κB/JNK-IN-1 exhibits an inhibitory effect on nitric oxide</p>Fórmula:C22H22N2O6Cor e Forma:SolidPeso molecular:410.42Autophagy-IN-1
<p>Autophagy-IN-1 blocks autophagy in cancer cells, hinders tumor growth in mice, and aids in studying colorectal cancer.</p>Fórmula:C23H25NO7Cor e Forma:SolidPeso molecular:427.45GLI1-IN-1
CAS:<p>GLI1-IN-1 (CBC-1), a GLI-1 inhibitor, exhibits superior water solubility and anticancer properties. It effectively induces apoptosis and inhibits colorectal cancer growth by targeting the Hedgehog (HH) pathway (IC 50 = 1.3 μM) [1].</p>Fórmula:C42H60N2O9Cor e Forma:SolidPeso molecular:736.93[D-Leu-4]-OB3
CAS:[D-Leu-4]-OB3 suppresses the expression of genes associated with inflammation, proliferation, and metastasis, as well as the expression of PD-L1.Fórmula:C29H50N8O12SCor e Forma:SolidPeso molecular:734.82DHU-Se1
<p>DHU-Se1: potent anti-inflammatory, releases reactive selenium from macrophages, inhibits iNOS/TNF-α, blocks M0 to M1 polarization.</p>Fórmula:C23H23N3OSSeCor e Forma:SolidPeso molecular:468.47pan-KRAS-IN-5
CAS:<p>Pan-KRAS-IN-5 (compound 15a) is a pan-KRAS translation inhibitor targeting 5′-UTR RNA G-quadruplexes (rG4s). It induces cell cycle arrest and promotes apoptosis in KRAS-driven cancer cells [1].</p>Fórmula:C31H36FIN4O2Cor e Forma:SolidPeso molecular:642.55Necrosis inhibitor 3
CAS:<p>Necrosis Inhibitor 3 (compound B3) effectively inhibits necrosis, demonstrating an IC50 of 0.29 nM in HT29 cells [1].</p>Fórmula:C25H26N4O4SCor e Forma:SolidPeso molecular:478.56GQN-B37-E
CAS:<p>GQN-B37-E is an effective selective binder and inhibitor of MCL-1. It binds to the BH3-binding domain of MCL-1. GQN-B37-E demonstrates binding affinity for MCL-1 within the sub-micromolar range (Ki= 0.6 μM), yet shows negligible binding to BCL-2 or BCL-XL.</p>Fórmula:C29H23ClN4O4Cor e Forma:SolidPeso molecular:526.97Topoisomerase I/II inhibitor 3
<p>Topoisomerase I/II inhibitor 3 suppresses cell growth and induces apoptosis in liver cancer by blocking PI3K/Akt/mTOR.</p>Fórmula:C24H24N2O4Cor e Forma:SolidPeso molecular:404.46PAK4-IN-5
<p>PAK4-IN-5 (Compound 12i) is a potent inhibitor of PAK4 (IC50: PAK4 at 7.68 nM, PAK1 at 1872.01 nM) that forms stable interactions with the PAK4 enzyme. This compound effectively inhibits the proliferation and migration potential of MDA-MB-231 cells by hindering the phosphorylation of PAK4 and LIMK1. Additionally, PAK4-IN-5 arrests the cell cycle in the G0/G1 phase, induces apoptosis, and prompts the production of reactive oxygen species. The LD50 in mice is greater than 500 mg/kg (oral).</p>Fórmula:C31H28ClN5OCor e Forma:SolidPeso molecular:522.04TNF-α-IN-2
CAS:<p>TNF-α-IN-2 is orally active TNFα inhibitor that distorts the TNFα trimer, causing abnormal signal transduction when it binds to TNFR1, rheumatoid arthritis.</p>Fórmula:C25H21ClF2N6OPureza:99.92%Cor e Forma:SolidPeso molecular:494.92HDAC-IN-81
CAS:<p>HDAC-IN-81 (Compound 11g) is an HDAC inhibitor capable of effectively inhibiting HDAC1 with an IC50 value of 4.5 nM. Additionally, it exhibits anticancer activity by inhibiting cell proliferation and can induce cell apoptosis (apoptosis).</p>Fórmula:C20H27N3O3Cor e Forma:SolidPeso molecular:357.45BRD-K20733377
CAS:<p>BRD-K20733377 is a Bcl-2 inhibitor that exhibits selective cytotoxicity toward senescent cells, specifically inhibiting the activity of etoposide-induced senescent IMR-90 cells with an IC50 of 10.7 μM. Additionally, BRD-K20733377 reduces the mRNA expression of aging-related genes p16, p21, and KI67 in aged mouse models.</p>Fórmula:C23H18N4O3SCor e Forma:SolidPeso molecular:430.48BRD-K44839765
CAS:<p>BRD-K44839765 selectively targets Bcl-2, exhibiting an IC50 of 5.6 μM in IMR-90 cells. This compound is also orally active.</p>Fórmula:C23H19N3O2S2Cor e Forma:SolidPeso molecular:433.55Soquelitinib
CAS:<p>Soquelitinib (CPI-818) is a selective ITK inhibitor， inhibits tumor growth,T-cell, up-regulatCXCR3, IFNγ, TNFα, and CD107a expression in normal CD8 cells.</p>Fórmula:C25H30N4O4S2Pureza:99.54%Cor e Forma:SolidPeso molecular:514.66ZSH-512
CAS:<p>ZSH-512 is a potent inhibitor of RARγ with antiproliferative properties. It induces apoptosis and reduces the expression of CD133, NANOG, SOX2, and EPCAM proteins. ZSH-512 exhibits anticancer activity and shows potential for colorectal cancer research.</p>Fórmula:C20H21N3O3SCor e Forma:SolidPeso molecular:383.464HL001
CAS:<p>HL001 is an orally active small molecule inhibitor of cyclophilin A (CypA) and a receptor antagonist of lysophosphatidic acid 1 (LPA1). It induces cell cycle arrest and apoptosis in tumor cells via p53. By downregulating G3BP1, HL001 promotes reactive oxygen species production and DNA damage to stabilize p53. It disrupts the interaction between MDM2 and p53-72R in a CypA-dependent manner. HL001 exhibits antitumor activity and can also be used in research on pulmonary fibrosis.</p>Fórmula:C21H16N2O4Cor e Forma:SolidPeso molecular:360.363DOR agonist 2
CAS:<p>Compound 3 (DOR agonist 2) acts as a Delta Opioid Receptor agonist. It inhibits the expression of TNF-α, obstructs NF-κB transportation to the nucleus, and activates the G protein-mediated ERK1/2 pathway. This compound is useful for research into neurodegenerative diseases.</p>Fórmula:C29H26N2O3Cor e Forma:SolidPeso molecular:450.53Sabialimon P
CAS:<p>Sabialimon P (compound 16), with an IC50 of 18.12 μM, functions as a NO release inhibitor and exhibits anti-inflammatory properties. It effectively diminishes the secretion of TNF-α, iNOS, IL-6, and NF-κB, and suppresses the expression of COX-2 and NF-κB/p65 in LPS-induced RAW264.7 cells.</p>Fórmula:C31H50O4Cor e Forma:SolidPeso molecular:486.73ASCT2-IN-1
CAS:ASCT2-IN-1 (compound 20k) is an inhibitor of ASCT2, demonstrating IC50 values of 5.6 μM in A549 cells and 3.5 μM in HEK293 cells. It induces apoptosis and inhibits tumor growth.Fórmula:C36H32Cl2N2O4Peso molecular:627.56N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride
CAS:<p>N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride (TLCK hydrochloride) is an irreversible serine protease inhibitor that functions by alkylating the histidine residue at the active site, thus inhibiting trypsin and trypsin-like proteases. It effectively inhibits caspase-3, caspase-6, and caspase-7 with IC50 values of 12.0, 54.5, and 19.3 μM, respectively. Additionally, N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride induces apoptosis in HL-60 cells and prevents the reduction of mitochondrial transmembrane potential during the apoptosis process.</p>Fórmula:C14H22Cl2N2O3SPeso molecular:369.31Tubulin/NRP1-IN-1
CAS:<p>Tubulin/NRP1-IN-1 (compound TN-2) serves as a dual inhibitor targeting both Tubulin and NRP1, exhibiting IC50 values of 0.71 μM and 0.85 μM, respectively. This compound notably reduces the viability of prostate tumor cell lines and triggers apoptosis [1].</p>Fórmula:C28H37N5O8Cor e Forma:SolidPeso molecular:571.62TNF-α-IN-14
CAS:<p>TNF-α-IN-14, a potent TNFα inhibitor, exhibits a selective inhibition profile with an IC50 of 1.1 µM and demonstrates antiinflammatory properties (WO2001072735A2; compound 12) [1].</p>Fórmula:C22H26O6Cor e Forma:SolidPeso molecular:386.44JR5-26B
CAS:<p>JR5-26B is an orally active apoptosis (apoptosis) inducer. It induces cell death via copper-mediated apoptosis and necroptosis (necroptosis). JR5-26B exhibits antiproliferative activity against MIA PaCa-2, PANC-1, PAN02, SU.86.86, and KPC-2 cells, with IC50 values of 0.6, 4.4, 8.0, 1.1, and 3.4 μM, respectively.</p>Fórmula:C19H17FN6OCor e Forma:SolidPeso molecular:364.38HDAC/PSMD14-IN-1
CAS:<p>HDAC/PSMD14-IN-1 is a derivative of gambogic acid. It serves as an orally active dual inhibitor targeting PSMD14 and HDAC1, with IC50 values of 238.7 nM and 141.2 nM, respectively. The compound exhibits significant cytotoxicity against ESCC cell lines (IC50: 30-250 nM) and effectively reverses epithelial-mesenchymal transition (EMT). Additionally, HDAC/PSMD14-IN-1 can induce apoptosis. In KYSE30 cell xenograft models in mice, it displays antitumor activity. HDAC/PSMD14-IN-1 is useful for researching esophageal cancer treatment.</p>Fórmula:C20H24N4O3S2Cor e Forma:SolidPeso molecular:432.56NiCur
CAS:<p>NiCur is an effective and selective inhibitor of CBP histone acetyltransferase (HAT), with an IC50 of 0.35 μM.</p>Fórmula:C22H16N2OPureza:99.22%Cor e Forma:SolidPeso molecular:324.38HBV/HDV-IN-2
CAS:<p>HBV/HDV-IN-2 (Compd 143) functions as an inhibitor for HBV, HDV, and PD-1/PD-L1, demonstrating an EC 50 of 35 nM in T cell activation.</p>Fórmula:C38H44ClN7O5Cor e Forma:SolidPeso molecular:714.25VDX-111
CAS:<p>VDX-111, an analog of vitamin D, exhibits cytotoxicity in ovarian cancer cells by upregulating the RIPK1/RIPK3 pathway and inducing necroptosis. It also promotes the expression of cytokines and demonstrates antitumor activity in a mouse model [1].</p>Fórmula:C29H45BrO4Cor e Forma:SolidPeso molecular:537.57Tubulin polymerization-IN-61
CAS:<p>Tubulin polymerization-IN-61 (Compound 9a), a tubulin polymerization inhibitor, disrupts the microtubule skeleton, arrests the cell cycle at the G2/M phase, induces Apoptosis, and impedes cancer cell migration and colony formation. This compound demonstrates antitumor efficacy in vivo within the 4T1 xenograft model [1].</p>Fórmula:C22H21N3O5Cor e Forma:SolidPeso molecular:407.42ASK1-IN-7
CAS:<p>ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. This compound is potentially applicable in research involving ASK1 signaling pathways, including studies on cellular stress response, inflammatory response, neurodegenerative diseases, and cardiovascular diseases.</p>Fórmula:C13H8N2O2S2Cor e Forma:SolidPeso molecular:288.345Tubulin inhibitor 41
CAS:<p>Tubulin inhibitor 41 (Compd D19) is a promising lead compound for glioblastoma treatment, known for its ability to penetrate the blood-brain barrier (BBB). It functions as a tubulin inhibitor, inducing G2/M phase arrest, leading to cell apoptosis, and inhibiting the migration of U87 cells [1].</p>Fórmula:C20H15N3OCor e Forma:SolidPeso molecular:313.35AKN-028 acetate
<p>AKN-028 acetate: an oral TK inhibitor for AML research, targets FLT3 with IC50 of 6 nM, inhibits autophosphorylation, and induces apoptosis.</p>Fórmula:C19H18N6O2Cor e Forma:SolidPeso molecular:362.39JH-XVII-10
<p>JH-XVII-10: potent, oral DYRK1A/B inhibitor (IC50: 3/5 nM), shows antitumor activity in HNSCC.</p>Fórmula:C21H16F4N8OCor e Forma:SolidPeso molecular:472.4Anti-inflammatory agent 16
<p>Compound 14 is a peptidomimetic that significantly lowers TNFα, NO, CD40, and CD86, showcasing strong anti-inflammatory effects.</p>Fórmula:C21H23N5O3Cor e Forma:SolidPeso molecular:393.44SphK1-IN-2
<p>SphK1-IN-2: SphK1 inhibitor, IC50: 19.81 nM; less effective on SphK2. Induces apoptosis, hinders cancer cell growth.</p>Fórmula:C27H30BrNO4SCor e Forma:SolidPeso molecular:544.5QTX125 TFA
<p>QTX125 TFA: Potent, selective HDAC6 inhibitor with antitumor effects.</p>Fórmula:C25H20F3N3O7Cor e Forma:SolidPeso molecular:531.44Ferroptosis-IN-6
CAS:<p>Ferroptosis-IN-6 is an efficient ferroptosis inhibitor, protecting cells from cell death induced by ferroptosis inducers, and inhibiting STY-BODIPY oxidation.</p>Fórmula:C15H17NOPureza:99.84%Cor e Forma:SolidPeso molecular:227.3RET-IN-10
CAS:<p>RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).</p>Fórmula:C29H28N8OSCor e Forma:SolidPeso molecular:536.65VEGFR-2-IN-15
<p>VEGFR-2-IN-15 (Compound 14b) is a potent inhibitor of VEGFR-2. VEGFR-2-IN-15 inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Fórmula:C23H18ClN3O4SCor e Forma:SolidPeso molecular:467.92p38 MAPK-IN-3
<p>Compound 2c is a potent p38α MAPK inhibitor with antitumor effects, enhancing apoptosis and ROS.</p>Fórmula:C22H17BrO2Cor e Forma:SolidPeso molecular:393.27Lepidozin G
<p>Lepidozin G blocks cancer growth (IC50=4.2-5.7μM) and triggers apoptosis in PC-3 cells via mitochondria.</p>Fórmula:C30H48O4Cor e Forma:SolidPeso molecular:472.7Bcl-2-IN-7
<p>Bcl-2-IN-7 inhibits Bcl-2, encourages apoptosis in cancer cells, and has anti-tumor activity with various IC50 values.</p>Fórmula:C24H22N4O5S2Cor e Forma:SolidPeso molecular:510.59RET-IN-7
CAS:<p>RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice through</p>Fórmula:C22H24ClFN6O2Cor e Forma:SolidPeso molecular:458.92CK156
CAS:<p>CK156 inhibits DAPK with high selectivity; IC50: 182 nM (DRAK1), 34 μM (CK2a1), 39 μM (CK2a2); key in autoimmune/inflammation research.</p>Fórmula:C21H25N5O3Cor e Forma:SolidPeso molecular:395.45Rezatapopt
CAS:<p>Rezatapopt (PC14586) is a p53 reactivator with antitumor activity for the study of locally advanced or metastatic solid tumors.</p>Fórmula:C28H31F4N5O2Pureza:98.12%Cor e Forma:SolidPeso molecular:545.57PI4KIII β inhibitor 4
CAS:<p>PI4KIII beta inhibitor 4 (Compound 16) is a selective inhibitor of PI4KIIIβ with an IC50 of 0.005 μM. By inhibiting the PI3K/AKT pathway, PI4KIII beta inhibitor 4 induces apoptosis, causes cell cycle arrest, and triggers autophagy in tumor cells. This compound is applicable for tumor research.</p>Fórmula:C24H36N4O6S2Cor e Forma:SolidPeso molecular:540.696Topoisomerase IIα-IN-4
<p>Topoisomerase IIα-IN-4 (F2) is a non-intercalative ATP-competitive inhibitor of human DNA topoisomerase II, specifically inhibiting TopoIIα with an IC50 value</p>Fórmula:C25H21NO2Cor e Forma:SolidPeso molecular:367.44CDK-IN-9
<p>CDK-IN-9: A potent CDK inhibitor, gels to enhance CDK12/DDB1 binding, targets CDK2/E (IC50: 4 nM), induces apoptosis via dephosphorylation.</p>Fórmula:C21H24N8SCor e Forma:SolidPeso molecular:420.53Anticancer agent 64
CAS:<p>Anticancer agent 64 (5m) induces apoptosis, has IC50 2.4μM in CCRF-CEM, activates caspases, cleaves PARP, affects mitochondria.</p>Fórmula:C31H46N2O2SCor e Forma:SolidPeso molecular:510.77Topo I/COX-2-IN-1
<p>Topo I/COX-2-IN-1: potent dual inhibitor; IC50 0.24μM (COX-2), 4.42μM (Topo I); anti-cancer; induces apoptosis, halts migration.</p>Fórmula:C21H18ClFN2O3Cor e Forma:SolidPeso molecular:400.83ASK1-IN-8
CAS:<p>ASK1-IN-8 (Compound 35) is an orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC50 value of 1.8 nM. In a mouse liver injury model induced by Acetaminophen, ASK1-IN-8 significantly reduces plasma alanine aminotransferase (ALT) levels, offering liver protection. This compound is useful for research in liver disease-related fields.</p>Fórmula:C26H32N8O2Cor e Forma:SolidPeso molecular:488.585XPO1-IN-1
<p>XPO1-IN-1: an oral MM.1S cell inhibitor (IC50: 24 nM), induces apoptosis, stable metabolism, good pharmacokinetics.</p>Fórmula:C20H15F6N5O3SCor e Forma:SolidPeso molecular:519.42Tubulin inhibitor 13
CAS:<p>Tubulin inhibitor 13 (E27), IC50 16.1 μM, blocks tubulin polymerization, cancer cell migration, and invasion, induces apoptosis.</p>Fórmula:C25H21N3O4Cor e Forma:SolidPeso molecular:427.45RET-IN-11
<p>RET-IN-11 selectively inhibits RET (IC50: 6.20 nM), promotes apoptosis, and hinders cell proliferation and migration.</p>Fórmula:C27H30FN9OCor e Forma:SolidPeso molecular:515.59CCT369260
CAS:<p>CCT369260 (compound 1), an orally active inhibitor targeting B-cell lymphoma 6 (BCL6), demonstrates anti-tumor efficacy with an IC50 value of 520 nM [1].</p>Fórmula:C24H31ClF2N6O2Cor e Forma:SolidPeso molecular:508.99MLKL-IN-6
<p>MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein.</p>Fórmula:C20H18N4O5Pureza:98%Cor e Forma:SolidPeso molecular:394.38BRD1991
CAS:<p>BRD1991 is a chemical compound that specifically disrupts the interaction between Beclin 1 and Bcl-2, thereby inducing autophagy.</p>Fórmula:C33H35Cl2N3O4Cor e Forma:SolidPeso molecular:608.55HDAC6/HSP90-IN-2
<p>HDAC6/HSP90-IN-2, a cancer research chemical, inhibits HDAC6 & Hsp90 with IC50s of 105.7 & 61 nM.</p>Fórmula:C19H22N2O5Cor e Forma:SolidPeso molecular:358.39Multi-kinase-IN-1
CAS:<p>Multi-kinase-IN-1, a powerful kinase inhibitor, exhibits antitumor properties by inducing cell apoptosis.</p>Fórmula:C35H36F2N6O6SCor e Forma:SolidPeso molecular:706.76AK-295
CAS:<p>AK 295, also known as CX 295, is a dipeptide inhibitor of alpha-ketoamide calpain.</p>Fórmula:C26H40N4O6Cor e Forma:SolidPeso molecular:504.62PD-1/PD-L1-IN-15
<p>PD-1/PD-L1-IN-15 is a potent inhibitor of PD-1/PD-L1 (IC50: 60.1 nM) and has shown investigational potential for tumor immunotherapy.</p>Fórmula:C32H30N4O3Cor e Forma:SolidPeso molecular:518.61HDAC-IN-27 dihydrochloride
CAS:<p>HDAC-IN-27 dihydrochloride (Compound 11h) is a potent, orally active, HDACI class-selective inhibitor, with IC50 values ranging from 0.43 to 3.01 nM for HDAC1-3. This compound exhibits both in vivo and in vitro anticancer activity. HDAC-IN-27 shows significant antiproliferative effects against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). It is useful for research on acute myeloid leukemia (AML).</p>Fórmula:C20H24Cl2N4O2Cor e Forma:SolidPeso molecular:423.3363-AP-Me
CAS:<p>3-AP-Me is the dimethyl derivative of the ribonucleotide reductase inhibitor 3-AP (SML0568). It activates the endoplasmic reticulum (ER) stress pathway by promoting eIF2α phosphorylation and upregulating gene expression of transcription factors ATF4 and ATF6, thereby inducing apoptosis. Additionally, 3-AP-Me activates cellular stress kinases c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase, leading to the upregulation of spliced mRNA variant XBP1. It is applicable in cancer research.</p>Fórmula:C9H13N5SCor e Forma:SolidPeso molecular:223.298PD-1-IN-17 TFA
<p>PD-1-IN-17 TFA is a potent PD-1 inhibitor, blocking 92% of splenocyte growth at 100 nM.</p>Fórmula:C15H23F3N6O9Cor e Forma:SolidPeso molecular:488.37XIAP degrader-1
<p>XIAP degrader-1 is a small primary amine molecule that promotes the degradation of X-linked apoptosis inhibitory protein (XIAP).</p>Fórmula:C34H45N5O4Cor e Forma:SolidPeso molecular:587.75PARP10/15-IN-3
<p>Compound 8a, a dual PARP10 & PARP15 inhibitor, has IC50s: PARP10 at 0.14μM & PARP15 at 0.40μM; it's cell-permeable & anti-apoptotic.</p>Fórmula:C12H12N2O3Cor e Forma:SolidPeso molecular:232.24Antitumor agent-77
<p>Antitumor agent-77 suppresses cancer cell growth, migration, induces apoptosis, and hinders EMT.</p>Fórmula:C7H11F3N2O5PtCor e Forma:SolidPeso molecular:455.25BMS-751324
CAS:<p>BMS-751324: p38α MAPK inhibitor with carbamyl-methyl, esters, phosphate from HPA. Reduces rat arthritis swelling and TNFα.</p>Fórmula:C32H35N6O10PCor e Forma:SolidPeso molecular:694.63GGTI298
CAS:<p>GGTI298 is a potent GGTase I inhibitor; IC50 3μM for Rap1A, >20μM for Ha-Ras.</p>Fórmula:C27H33N3O3SPureza:98%Cor e Forma:SolidPeso molecular:479.63MTDH-SND1 blocker 2
CAS:<p>MTDH-SND1 blocker 2 (compound C19) is an effective MTDH-SND1 inhibitor with an IC50 value of 487 nM. It binds to the SND1 protein with a Kd of 279 nM and can degrade the SND1 protein. Additionally, MTDH-SND1 blocker 2 exhibits antiproliferative activity and induces apoptosis, showing potential for breast cancer research.</p>Fórmula:C18H12FN3O2SCor e Forma:SolidPeso molecular:353.37MTX-216
CAS:<p>MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.</p>Fórmula:C22H14Cl2FN5O2SCor e Forma:SolidPeso molecular:502.3483′-Hydroxyflavanone
CAS:<p>3′-Hydroxyflavanone is a cyclized flavonoid with anti-tumor properties that induces apoptosis in HeLa cells.</p>Fórmula:C15H12O3Cor e Forma:SolidPeso molecular:240.25CRI9
<p>CRI9 effectively inhibits the c-MET/PI3K/Akt/mTOR axis, suppressing the proliferation of hepatocellular carcinoma (HCC) cells. This compound exhibits potent cytotoxicity against HCC cells and induces apoptosis.</p>Fórmula:C26H18N6O4Cor e Forma:SolidPeso molecular:478.46EGFR/VEGFR2-IN-3
CAS:<p>EGFR/VEGFR2-IN-3 (compound 9) is an effective inhibitor of EGFR and VEGFR-2, demonstrating IC50 values of 0.129 µM for EGFR, 0.142 µM for VEGFR-2, and 3.428 µM for COX-2. This compound exhibits cytotoxic properties and induces cell apoptosis (apoptosis) as well as cell cycle arrest at the G2/M phase.</p>Fórmula:C24H20ClN5O2S2Cor e Forma:SolidPeso molecular:510.03EGFR-IN-134
<p>EGFR-IN-134 (compound 3f) is a triazolo[3,4-a]quinoline derivative and functions as a potent EGFR inhibitor with an IC50 of 0.023 µM. It induces apoptosis and necrosis in cells, and causes cell cycle arrest in the G2/M and pre-G1 phases. EGFR-IN-134 modulates the expression of apoptosis-regulating proteins by downregulating anti-apoptotic protein Bcl2 and upregulating pro-apoptotic proteins p53, Bax, and caspases 3, 8, and 9, demonstrating significant antiproliferative and anticancer activities.</p>Fórmula:C36H30N6O5Cor e Forma:SolidPeso molecular:626.66c-Met/HDAC-IN-2
CAS:<p>Potent dual c-Met/HDAC inhibitor, IC50: HDAC1 5.4 nM, c-Met 18.49 nM; anti-cancer, induces apoptosis, G2/M arrest in HCT-116.</p>Fórmula:C34H33N5O7Cor e Forma:SolidPeso molecular:623.66Antiproliferative agent-8
<p>Compound 5a, an anticancer agent, enhances P53 and has antiproliferative effects.</p>Fórmula:C22H16ClN3O3Cor e Forma:SolidPeso molecular:405.83NLRP3-IN-26
CAS:<p>NLRP3-IN-26 (compound 15Z), with an IC50 of 0.13 μM, functions as an inhibitor of NLRP3. It is applicable in studies involving the DSS-induced colitis model [1].</p>Fórmula:C31H33ClN2O6SCor e Forma:SolidPeso molecular:597.12MY-875
<p>MY-875 inhibits microtubule formation, binds like colchicine (IC50: 0.92 μM), activates Hippo pathway, and induces apoptosis with anticancer properties.</p>Fórmula:C21H25NO6Cor e Forma:SolidPeso molecular:387.43FLT3-ITD-IN-3
CAS:<p>FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).</p>Fórmula:C27H21ClF2N6O5Cor e Forma:SolidPeso molecular:582.943PARP1/BRD4-IN-2
<p>PARP1/BRD4-IN-2, a potent inhibitor of PARP1 and BRD4, halts cell cycle, triggers apoptosis, and has antitumor effects on TNBC.</p>Fórmula:C25H20N4O4Cor e Forma:SolidPeso molecular:440.45ABL-L
CAS:<p>ABL-L is able to induce apoptosis in human laryngeal cancer cells using a p53-dependent pathway.</p>Fórmula:C29H46O6Cor e Forma:SolidPeso molecular:490.67ZLMT-12
<p>ZLMT-12: tacrine derivative, inhibits CDK2/CDK9, weak on AChE/BuChE, anti-proliferative, low toxicity, blocks S/G2/M phase, induces apoptosis.</p>Fórmula:C26H31ClN6OCor e Forma:SolidPeso molecular:479.02SMIP34
CAS:<p>SMIP34 is an inhibitor of PELP1, binding to this target with a dissociation constant (Kd) of 37.4 μM. It demonstrates efficacy in inhibiting the proliferation of cancer cells and tumor progression. Specifically, SMIP34 is effective in breast cancer research, showing activity against wild-type (WT), mutant (MT) estrogen receptor-positive (ER+), and treatment-resistant (TR)-ER+ breast cancers.</p>Fórmula:C25H32ClN5O3Cor e Forma:SolidPeso molecular:486.01Belotecan
CAS:<p>Belotecan (CKD-602) inhibits DNA topoisomerase I, blocks cell cycle, induces apoptosis, and is a camptothecin-derived anticancer agent.</p>Fórmula:C25H27N3O4Cor e Forma:SolidPeso molecular:433.5Metamizole hemimagnesium
CAS:<p>Metamizole (Dipyrone) hemimagnesium is an anti-inflammatory and antioxidant compound known for its ability to reduce fever. It decreases levels of C-reactive protein (CRP) and interleukin 6 (IL-6). Additionally, Metamizole hemimagnesium acts as an orally active cyclooxygenase (COX) inhibitor, suppressing cell proliferation and promoting apoptosis. It is utilized in the study of inflammation and fever.</p>Fórmula:C13H17MgN3O4SCor e Forma:SolidPeso molecular:335.662Bomedemstat hydrochloride
<p>Bomedemstat (IMG-7289) hydrochloride, an oral LSD1 inhibitor, has anticancer properties, blocking cell growth and triggering apoptosis.</p>Fórmula:C28H35ClFN7O2Cor e Forma:SolidPeso molecular:556.08FLT3-IN-13
<p>FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.</p>Fórmula:C20H14N4O2Cor e Forma:SolidPeso molecular:342.35VNPP433-3β
CAS:<p>VNPP433-3β acts as a molecular glue degrader, targeting the androgen receptor (AR) and its splice variants (AR-Vs) as well as MAP kinase-interacting serine/threonine protein kinase Mnk1/2. It effectively inhibits the proliferation of cancer cells LNCaP, C4-2B, and CWR22Rv1, with GI50 values of 0.2, 0.3, and 0.31 μM, respectively. Additionally, VNPP433-3β shows favorable pharmacokinetics in CD-1 mice and suppresses tumor growth in the CWR22Rv1 xenograft mouse model.</p>Fórmula:C29H34N4Cor e Forma:SolidPeso molecular:438.61VEGFR-2-IN-18
<p>VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.</p>Fórmula:C20H13ClN4O2Cor e Forma:SolidPeso molecular:376.8Ganoderic acid R
CAS:<p>Ganoderic acid R: potent anticancer, induces apoptosis, cytotoxic to MDR and sensitive tumor cells.</p>Fórmula:C34H50O6Cor e Forma:SolidPeso molecular:554.76XIAP/cIAP1 antagonist-1
<p>Potent oral XIAP/cIAP1 inhibitor with EC50s: XIAP 5.1 nM, cIAP1 0.32 nM; curbs tumor growth in vivo.</p>Cor e Forma:SolidTOPOI/PARP-1-IN-1
CAS:<p>Compound B6, also known as TOPOI/PARP-1-IN-1, is a dual inhibitor targeting TOPOI and PARP, exhibiting low cytotoxicity and oral activity with a PARP1 IC 50 of 0.09 μM. This compound effectively inhibits cancer cell proliferation and migration, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. In murine models, TOPOI/PARP-1-IN-1 demonstrated a tumor growth inhibition rate (TGI) of 75.4% [1].</p>Fórmula:C36H38Br2N4O2Cor e Forma:SolidPeso molecular:718.52MG-B-28
<p>MG-B-28, a BTLA-HVEM inhibitor, demonstrates an IC50 value of 906 nM. It promotes T cell activation dose-dependently by inhibiting the interaction between BTLA and HVEM.</p>Fórmula:C28H25N5O3Cor e Forma:SolidPeso molecular:479.53RWJ-56110
CAS:<p>protease-activated receptor-1 (PAR1) antagonist</p>Fórmula:C41H43Cl2F2N7O3Pureza:98%Cor e Forma:SolidPeso molecular:790.73LSD1/ER-IN-1
<p>LSD1/ER-IN-1 inhibits ER & LSD1 (IC50: 1.55 μM), and fights MCF-7 breast cancer (IC50: 8.79 μM).</p>Fórmula:C23H18FNO6SCor e Forma:SolidPeso molecular:455.46YCW-E11
CAS:<p>YCW-E11 is an antiapoptotic Bcl-2 family proteins inhibitor.</p>Fórmula:C25H21Cl2N3O6S2Pureza:98%Cor e Forma:SolidPeso molecular:594.49MD102
CAS:<p>MD102, with an IC50 value of 0.35 μM, is a potent TG2 inhibitor that stabilizes p53 by inhibiting TG2. This results in a decrease in p-AKT and p-mTOR downstream signaling, ultimately inducing tumor cell apoptosis [1].</p>Fórmula:C13H4BrCl2FN2O2Cor e Forma:SolidPeso molecular:389.99ADH-6
CAS:<p>ADH-6, a tripyridylamide, disrupts mutant p53 aggregates in cancer cells, reviving its function and inducing apoptosis.</p>Fórmula:C29H36N8O9Cor e Forma:SolidPeso molecular:640.64Topo I-IN-1
<p>Topo I-IN-1 (14d) is a powerful Topo I inhibitor with antitumor effects and DNA intercalation, inducing apoptosis.</p>Fórmula:C20H14BrN3O2Cor e Forma:SolidPeso molecular:408.25MA242
CAS:<p>MA242 is a nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy and dual inhibitor of murine double minute 2 (MDM2).</p>Fórmula:C26H21ClF3N3O5SPureza:98%Cor e Forma:SolidPeso molecular:579.98PI3K/AKT-IN-1
CAS:<p>PI3K/AKT-IN-1 is a dual inhibitor of PI3K and AKT with anti-cancer activity, inhibiting the PI3K/AKT pathway and inducing caspase 3-dependent apoptosis.</p>Fórmula:C23H23N5O4SPureza:99.84%Cor e Forma:SoildPeso molecular:465.53Ivaltinostat formic
<p>Ivaltinostat (CG-200745) is an oral panHDAC inhibitor, inducing apoptosis and enhancing cancer drug sensitivity.</p>Fórmula:C25H35N3O6Cor e Forma:SolidPeso molecular:473.56Tubulin inhibitor 14
<p>Tubulin inhibitor 14 blocks NQO2 and microtubule formation, disrupts blood vessels, and may target tumors; IC50 of 1.0 μM.</p>Fórmula:C15H9F2NOCor e Forma:SolidPeso molecular:257.23Tubulin inhibitor 43
CAS:<p>Tubulin inhibitor 43 exhibits significant antitumor activity by impeding the proliferation and growth of cancer cells through the inhibition of β-microtubulin activity, ultimately inducing apoptosis [1].</p>Fórmula:C20H21NO6Cor e Forma:SolidPeso molecular:371.38Antitumor agent-43
<p>Antitumor agent-43 (Compound 4B) is a potent antitumor agent that induces cell cycle arrest at G2/M phase.</p>Fórmula:C16H8N2O3Cor e Forma:SolidPeso molecular:276.25RIPK1-IN-24
CAS:<p>RIPK1-IN-24 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 of 1.3 μM. It is utilized in research on inflammatory diseases.</p>Fórmula:C26H21FN6O2Cor e Forma:SolidPeso molecular:468.48Tandutinib sulfate
CAS:<p>Tandutinib (MLN518) sulfate is an effective and selective inhibitor of FLT3, with an IC50 value of 0.22 μM. It also inhibits c-Kit and PDGFR, displaying IC50 values of 0.17 μM and 0.20 μM respectively. This compound can be utilized in the treatment of acute myeloid leukemia and has the capability to cross the blood-brain barrier.</p>Fórmula:C31H44N6O8SCor e Forma:SolidPeso molecular:660.78Nenocorilant
CAS:<p>Nenocorilant (Relacorilant) is an orally active glucocorticoid receptor (GR) antagonist (Ki: 0.15 nM). Nenocorilant can be used to study tumours.</p>Fórmula:C26H21F4N7O3SCor e Forma:SolidPeso molecular:587.55Ferrostatin-1 diyne
CAS:<p>Ferrostatin-1 diyne (Fer-1 diyne) (compound 2) serves as an inhibitor of ferroptosis, accumulating in cellular lysosomes, mitochondria, and the endoplasmic reticulum. It notably inhibits ferroptosis independently of lysosomal and mitochondrial activity.</p>Fórmula:C18H22N2O2Cor e Forma:SolidPeso molecular:298.38JAK-2/3-IN-3
<p>JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.</p>Fórmula:C13H10Cl2N4O2Cor e Forma:SolidPeso molecular:325.15JAK2/FLT3-IN-1 TFA
<p>JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).</p>Fórmula:C27H35F4N7O3Cor e Forma:SolidPeso molecular:581.61Antitumor agent-78
<p>Antitumor agent-78 blocks GPx-4, raises COX2, triggers apoptosis, halts EMT, and stifles cancer cell growth and migration.</p>Cor e Forma:SoildAnticancer agent 45
<p>Anticancer agent 46, potent and selective, induces apoptosis, is cytotoxic to cancer cells, with low toxicity to human lymphocytes.</p>Fórmula:C22H14ClN3O6S2Cor e Forma:SolidPeso molecular:515.95RIPK1-IN-14
CAS:<p>RIPK1-IN-14 inhibits RIPK1 with 92 nM IC50 and reduces necrotic apoptosis in U937 cells.</p>Cor e Forma:SoildHDAC-IN-9
<p>HDAC-IN-9, a dual tubulin/HDAC inhibitor, impedes A549 cell invasion/migration and shows strong anti-tumor/angiogenic effects.</p>Fórmula:C33H38N2O4Cor e Forma:SolidPeso molecular:526.67AZD0424
CAS:<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Fórmula:C25H29ClN6O5Pureza:98%Cor e Forma:SolidPeso molecular:528.99Topo II/HDAC-IN-2
CAS:<p>Topo II/HDAC-IN-2 (8d) demonstrates remarkable dual inhibitory effects on Topo II and HDAC, and also induces apoptosis [1].</p>Fórmula:C17H20N4O3SCor e Forma:SolidPeso molecular:360.43Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride
CAS:<p>Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate, comprised of a cereblon ligand based on Thalidomide and a linker, utilized in the synthesis of PROTACs.</p>Fórmula:C21H28ClN5O7Peso molecular:497.93Topo II/HDAC-IN-1
CAS:Topo II/HDAC-IN-1 (7d) demonstrates potent dual inhibitory effects on Topo II and HDAC, while Topo II/HDAC-IN-1 (8d) effectively induces apoptosis [1].Fórmula:C15H16N4O3SCor e Forma:SolidPeso molecular:332.38Sinulatumolin E
CAS:<p>Sinulatumolin E, a terpenoid, inhibits TNF-α (IC 50: 3.6 μM); has anti-inflammatory properties.</p>Fórmula:C15H22O2Cor e Forma:SolidPeso molecular:234.33NCAO
CAS:<p>N-ω-chloroacetyl-L-ornithine (NCAO) serves as a powerful reversible competitive inhibitor of ornithine decarboxylase (ODC), displaying cytotoxic and antiproliferative properties against various tumor cell lines, with EC50 values spanning from 1 to 50.6 µM. In vitro studies reveal that NCAO promotes Apoptosis and restricts tumor cell migration. Additionally, it demonstrates significant antitumor efficacy in a mouse model, targeting both solid and ascitic tumors using the myeloma (Ag8) cell line. NCAO holds promise in the development of antitumor agents.</p>Fórmula:C7H13ClN2O3Cor e Forma:SolidPeso molecular:208.64PIM1-IN-3
<p>PIM1-IN-3 (HL8) selectively blocks PIM1, induces Colo320 cell apoptosis, and may be researched for cancer.</p>Fórmula:C27H25BrN6OCor e Forma:SolidPeso molecular:529.43ZLWT-37
<p>ZLWT-37: Oral CDK inhibitor, CDK9 IC50=0.002 µM, CDK2 IC50=0.054 µM; halts HCT116 cells at G2/M, induces apoptosis.</p>Fórmula:C26H30ClN5OCor e Forma:SolidPeso molecular:464BRD4/CK2-IN-1
CAS:<p>BRD4/CK2-IN-1 is a small-molecule inhibitor targeting BRD4 and CK2, inducing apoptosis and autophagy-related cell death.</p>Fórmula:C29H30ClN5O5Pureza:99.02%Cor e Forma:SolidPeso molecular:564.03p53 Activator 14
CAS:<p>p53 Activator 14 (Compound 7A) is a derivative of Neratinib that can induce DNA damage and activate p53, thereby inhibiting the proliferation of various cancer cells, with an IC50 of 7.21 μM for HCT116 cells. This compound hinders adhesion, migration, and invasion of HCT116 cells, disrupts the cell cycle, and triggers apoptosis. In addition, p53 Activator 14 exhibits anti-tumor properties and inhibits angiogenesis in the chick embryo chorioallantoic membrane (CAM) model.</p>Fórmula:C28H29ClN4O3Cor e Forma:SolidPeso molecular:505.008Thalidomide-Piperazine-PEG1-NH2
CAS:<p>Thalidomide-Piperazine-PEG1-NH2 is a synthetic E3 ligase ligand-linker conjugate, featuring a cereblon ligand based on Thalidomide and a single linker.</p>Fórmula:C21H27N5O5Peso molecular:429.47HER2-IN-11
<p>HER2-IN-11 is a psoralen derivative that induces apoptosis. HER2-IN-11 shows light-activated cytotoxicity and also exhibits anti-breast cancer activity [1].</p>Fórmula:C17H11NO6Cor e Forma:SolidPeso molecular:325.27Pan-Trk-IN-3
<p>Pan-Trk-IN-3: potent Trk inhibitor (IC50: 2-26 nM), effective against drug-resistant mutants, induces apoptosis, anti-tumor effects.</p>Fórmula:C29H31ClN8O3Cor e Forma:SolidPeso molecular:575.06eIF4E-IN-4
CAS:<p>eIF4E-IN-4 (Compound 33) is a selective inhibitor of the eukaryotic initiation factor 4E (eIF4E) with a biochemical activity value of 95 nM. It inhibits cap-dependent mRNA translation with an IC50 of 2.5 μM and is applicable in research on breast cancer, colon cancer, and head and neck cancer.</p>Fórmula:C20H19ClN5O5PCor e Forma:SolidPeso molecular:475.822Mcl-1 inhibitor 9
CAS:<p>Mcl-1 Inhibitor 9 (Example 2) is a potent inhibitor of myeloid cell leukemia 1 (Mcl-1), demonstrating anti-tumor activity with an IC50 value of 0.21889 nM.</p>Fórmula:C32H39ClN2O5SCor e Forma:SolidPeso molecular:599.18NSC308848
CAS:<p>NSC308848 is an effective apoptosis (cell death) inducer that operates in a Myc-dependent manner. It acts by inhibiting Myc transactivation and disrupting the DNA binding activity of Myc family proteins.</p>Fórmula:C18H21N3O2Cor e Forma:SolidPeso molecular:311.378BCL6-IN-3
CAS:<p>BCL6-IN-3: potent BCL6 inhibitor, 70 nM GI50 in SU-DHL4, affects cell functions, antitumor.</p>Fórmula:C24H31ClF2N6O2Pureza:98.17%Cor e Forma:SolidPeso molecular:508.99UH15-38
CAS:<p>UH15-38 is a potent and selective RIPK3 inhibitor that blocks necroptosis in alveolar epithelial cells triggered by IAV, useful for studying lung inflammation.</p>Fórmula:C26H27N5O2Pureza:99.85%Cor e Forma:SolidPeso molecular:441.53PF-07328948
CAS:<p>PF-07328948 is a branched-chain keto-acid dehydrogenase kinase (BDK) inhibitor, useful for studying CVD metabolic disorders.</p>Fórmula:C16H8F4O3SPureza:98.42%Cor e Forma:SolidPeso molecular:356.29Zotatifin
CAS:<p>Zotatifin (eFT226) is a selective eIF4A inhibitor with antiviral and antitumor properties, inhibiting Sox4 translation and inducing apoptosis.</p>Fórmula:C28H29N3O5Pureza:98.85%Cor e Forma:SolidPeso molecular:487.55Tuvusertib
CAS:<p>Tuvusertib (M1774), an oral ATR inhibitor (Ki<1µM), selectively blocks CHK1 phosphorylation, disrupts DNA repair, and induces tumor cell apoptosis.</p>Fórmula:C16H12F2N8OPureza:98.44% - 99.66%Cor e Forma:SolidPeso molecular:370.32Lometrexol
CAS:<p>Lometrexol (LY 264618) is an antifolate that inhibits GARFT, blocks purine synthesis, induces apoptosis, and has anticancer properties.</p>Fórmula:C21H25N5O6Pureza:97.76% - 99.56%Cor e Forma:SolidPeso molecular:443.45HC-5404
CAS:<p>HC-5404 is a potent and selective PERK inhibitor, blocking the activation of the PERK pathway, anti-tumor effects, advanced solid tumors and renal cell Cancer.</p>Fórmula:C24H24F2N4O3Pureza:99.33%Cor e Forma:SolidPeso molecular:454.47Milademetan
CAS:<p>Milademetan (DS-3032), an MDM2 inhibitor, exhibits antitumor activity, induces G1 cell cycle arrest and apoptosis, and can be used to study solid tumors.</p>Fórmula:C30H34Cl2FN5O4Pureza:>99.99%Cor e Forma:SolidPeso molecular:618.53SY-5609
CAS:<p>SY-5609 (CDK7-IN-3) is a selective non-covalent CDK7 inhibitor, with weak inhibitory activity against CDK2, CDK9 and CDK12.Cost-effective and quality-assured.</p>Fórmula:C23H26F3N6OPPureza:99.34% - >99.99%Cor e Forma:SolidPeso molecular:490.46Vatalanib hydrochloride
CAS:<p>Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.</p>Fórmula:C20H16Cl2N4Pureza:99.7%Cor e Forma:SolidPeso molecular:383.27JAK2-IN-7
CAS:<p>JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.</p>Fórmula:C26H33N7OPureza:99.54%Cor e Forma:SolidPeso molecular:459.59Gemcitabine elaidate hydrochloride
CAS:<p>CP-4126, a lipophilic pro-drug of Gemcitabine, converts to active form by esterases, allowing oral administration with dose-dependent effects.</p>Fórmula:C27H44ClF2N3O5Pureza:98.50% - 99.6%Cor e Forma:SolidPeso molecular:564.11FX-11
CAS:<p>FX-11: potent LDHA inhibitor (Ki 8 μM), activates PKM2, reduces ATP, induces oxidative stress/ROS, cell death, shows antitumor effects.</p>Fórmula:C22H22O4Pureza:98.95%Cor e Forma:SolidPeso molecular:350.41β-Zearalanol
CAS:Beta-Zearalenol, a derivative of zearalenone (ZEA) capable of conjugating with glucuronic acid[2], is a mycotoxin produced by Fusarium spp. It induces apoptosis and oxidative stress in mammalian reproductive cells[1].Fórmula:C18H26O5Cor e Forma:SolidPeso molecular:322.4PIM-447 dihydrochloride
CAS:<p>PIM-447 dihydrochloride is an orally available and selective inhibitor of pan-PIM kinase(Ki values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively).</p>Fórmula:C24H25Cl2F3N4OPureza:98%Cor e Forma:SolidPeso molecular:513.38(R)-Verapamil hydrochloride
CAS:<p>(R)-Verapamil hydrochloride ((R)-(+)-Verapamil hydrochloride) is an inhibitor of P-Glycoprotein.</p>Fórmula:C27H39ClN2O4Cor e Forma:SolidPeso molecular:491.06OBAA
CAS:<p>OBAA is a potent inhibitor of phospholipase A2 (PLA2) with an IC 50 of 70 nM. OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei with an IC 50 of 0.4 μM [1] [2] [3].</p>Fórmula:C28H44O3Pureza:98%Cor e Forma:SolidPeso molecular:428.65WEHI-539 hydrochloride
CAS:<p>WEHI-539 hydrochloride is a selective Bcl-XL inhibitor with an IC50 of 1.1 nM.</p>Fórmula:C31H30ClN5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:620.18Actinonin
CAS:<p>Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces and a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. It also induces apoptosis and inhibits aminopeptidase M, aminopeptidase N, and leucine aminopeptidase, as well as MMP-1, MMP-3, MMP-8, MMP-9, and meprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin exhibits antiproliferative and antitumor activities [1][2][3][4][5].</p>Fórmula:C19H35N3O5Cor e Forma:SolidPeso molecular:385.5AP1867-3-(aminoethoxy)
CAS:<p>AP1867-3-(aminoethoxy) is a synthetic ligand for FKBP and can be used in the synthesis of PROTAC FKBP12 F36V degrader.</p>Fórmula:C38H50N2O9Cor e Forma:SolidPeso molecular:678.815-Amino-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide
CAS:Fórmula:C9H14N4O5Pureza:95%Cor e Forma:SolidPeso molecular:258.2313Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-
CAS:Fórmula:C6H10N2O4PtPureza:98%Cor e Forma:SolidPeso molecular:369.2326Ref: IN-DA00I84B
Produto descontinuadoAc-IETD-CHO TFA
<p>Ac-IETD-CHO TFA is a granzyme B and caspase-8 inhibitor that inhibits caspase8 activity by blocking caspase3 precursor cleavage.Ac-IETD-CHO TFA inhibits Fas-mediated apoptosis.</p>Fórmula:C23H35F3N4O12Cor e Forma:SoildPeso molecular:616.54RRD-251
CAS:<p>RRD-251 is an Rb-Raf-1 interaction inhibitor that induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine[1].</p>Fórmula:C8H9Cl3N2SCor e Forma:SolidPeso molecular:271.59XMU-MP-3
CAS:<p>XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.</p>Fórmula:C27H27F3N8OCor e Forma:SolidPeso molecular:536.563Swainsonine
CAS:<p>Swainsonine (Tridolgosir) is an alkaloid isolated from Astragalus membranaceus and is a potent and reversible inhibitor of alpha-mannosidase. swainsonine has antitumour activity and induces apoptosis and cell cycle arrest in the G2/M phase.</p>Fórmula:C8H15NO3Pureza:98%Cor e Forma:Lyophilized PowderPeso molecular:173.21Carubicin hydrochloride
CAS:<p>Carubicin HCl is an anthracycline antineoplastic antibiotic. Through intercalates into DNA and interacts with topoisomerase II, Carubicin inhibits DNA replication and repair and RNA and protein synthesis.</p>Fórmula:C26H28ClNO10Cor e Forma:SolidPeso molecular:549.95Ciprofloxacin lactate
CAS:<p>Ciprofloxacin lactate is a useful organic compound for research related to life sciences. The catalog number is T66299 and the CAS number is 97867-33-9.</p>Fórmula:C20H24FN3O6Cor e Forma:SolidPeso molecular:421.43Prostaglandin A2
CAS:<p>PGA2 is a naturally occurring prostaglandin in gorgonian corals where it may function in self defense. It is generally not present in mammals. PGA2 has low biological potency in most bioassays, but it does show some antiviral/antitumor activity.[1] At a 25 uM concentration, PGA2 blocks the cell cycle progression of NIH 3T3 cells at the G1 and G2/M phase .[2] It has also been shown to act as a vasodilator with natriuretic properties.[3]</p>Fórmula:C20H30O4Cor e Forma:SolidPeso molecular:334.45Thalidomide-5-COOH
CAS:<p>Thalidomide-5-COOH is a useful organic compound for research related to life sciences. The catalog number is T64600 and the CAS number is 1216805-11-6.</p>Fórmula:C14H10N2O6Cor e Forma:SolidPeso molecular:302.242Yatein
CAS:<p>Yatein inhibits herpes simplex virus type 1 replication by interruption the immediate-early gene expression. Yatein is a lignan isolated from A. chilensis. It also has antiproliferative activity.</p>Fórmula:C22H24O7Pureza:98%Cor e Forma:SolidPeso molecular:400.42A-192621
CAS:<p>A-192621 is a potent, nonpeptide, orally active, and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. A-192621 promotes apoptosis in PASMCs and elevates both arterial blood pressure and plasma ET-1 levels[1][2][3]. Its selectivity is 636-fold higher for ETB than ETA (IC50 of 4280 nM and Ki of 5600 nM).</p>Fórmula:C33H38N2O6Pureza:98%Cor e Forma:SolidPeso molecular:558.66Thalidomide-O-C5-NH2 hydrochloride
CAS:<p>Thalidomide-O-C5-NH2 hydrochloride is a synthetic compound consisting of a ligand-linker conjugate with E3 ligase activity. It combines a cereblon ligand based on Thalidomide and a linker commonly utilized in PROTAC technology.</p>Fórmula:C18H22ClN3O5Cor e Forma:SolidPeso molecular:395.84Ingenol 3,20-dibenzoate
CAS:<p>Ingenol 3,20-dibenzoate is a powerful activator of protein kinase C (PKC) isoforms that effectively induces the translocation of nPKC-delta, -epsilon, and -theta, as well as PKC-mu, from the cytosolic fraction to the particulate fraction. Through de novo synthesis of macromolecules, it triggers apoptosis with characteristic morphology. Moreover, Ingenol 3,20-dibenzoate enhances IFN-γ production and degranulation in NK cells, particularly when stimulated by NSCLC cells[1][2].</p>Fórmula:C34H36O7Cor e Forma:SolidPeso molecular:556.65Thalidomide-O-C6-COOH
CAS:<p>Thalidomide-O-C6-COOH is a synthetic conjugate that combines a Thalidomide-derived cereblon ligand with a PROTAC technology linker (E3 ligase ligand-linker).</p>Fórmula:C20H22N2O7Cor e Forma:SolidPeso molecular:402.403DB818
CAS:<p>DB818 is a synthetic Homeobox A9 (HOXA9) inhibitor and can be used for research on the treatment of acute myeloid leukaemia associated with HOXA9 overexpression.</p>Fórmula:C19H16N6SPureza:98%Cor e Forma:SolidPeso molecular:360.44ENMD-2076 tartrate
CAS:<p>ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.</p>Fórmula:C25H31N7O6Cor e Forma:SolidPeso molecular:525.56Thalidomide-O-amido-C4-NH2 hydrochloride
CAS:<p>Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].</p>Fórmula:C19H23ClN4O6Pureza:98%Cor e Forma:SolidPeso molecular:438.86SCH79797
CAS:<p>SCH79797 is a potent and specific protease-activated receptor 1 (PAR1) antagonistwith antimicrobial, anticancer, anti-inflammatory, and neuroprotective effects.</p>Fórmula:C23H25N5Pureza:99.80%Cor e Forma:SolidPeso molecular:371.48Imifoplatin
CAS:<p>Imifoplatin (PT-112) is a platinum compound with antitumor activity and may be used to study prostate cancer and immune system disorders.</p>Fórmula:C6H16N2O7P2PtPureza:≥95.0%Cor e Forma:SolidPeso molecular:485.23MI-773
CAS:<p>MI-773 is a potent inhibitor of the MDM2-p53 protein interaction (PPI) with a high affinity for MDM2 and a Kd value of 8.2 nM. MI-773 exhibits antitumour effects.</p>Fórmula:C29H34Cl2FN3O3Cor e Forma:SolidPeso molecular:562.5Vatiquinone
CAS:<p>Vatiquinone, also known as EPI 743, is an orally bioavailable para-benzoquinone being developed for inherited mitochondrial diseases. The mechanism of action of EPI-743 involves augmenting the synthesis of glutathione, optimizing metabolic control, enhanc</p>Fórmula:C29H44O3Cor e Forma:SolidPeso molecular:440.66Mcl-1 inhibitor 6
CAS:<p>Mcl-1 inhibitor 6 binds Mcl-1 with KD 0.23 nM and Ki 0.02 μM, shows strong selectivity over Bcl-2 family, and demonstrates antitumor efficacy.</p>Fórmula:C26H28ClNO6SCor e Forma:SolidPeso molecular:518.02CTB
CAS:<p>CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.</p>Fórmula:C16H13ClF3NO2Pureza:99.82%Cor e Forma:SolidPeso molecular:343.73anti-TNBC agent-2
CAS:<p>Anti-TNBC agent-2 (3j), a purine derivative, acts as an anti-triple negative breast cancer (TNBC) therapeutic.</p>Fórmula:C28H37ClFN7OPureza:98%Cor e Forma:SolidPeso molecular:542.09Ref: TM-T79699
Produto descontinuadoTaltobulin
CAS:<p>Taltobulin (HTI-286) is a synthetic analog of the tripeptide cysteine, a microtubule protein inhibitor that inhibits liver tumor cell proliferation in vitro and tumor growth in vivo.Taltobulin is cytotoxic, induces mitotic arrest and apoptosis, and may be used in the study of breast cancer and microtubule tissue-related diseases.</p>Fórmula:C27H43N3O4Pureza:99.86%Cor e Forma:SolidPeso molecular:473.65DETD-35
CAS:<p>DETD-35 is a promising chemical compound in anti-melanoma therapy, functioning as an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways. It enhances cancer cell apoptosis (Apoptosis) and diminishes resistance to Vemurafenib in cancer cells. The compound exhibits IC 50 values of 2.7, 6.0, 3.9, 3.1, and 2.5 μM against melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c, respectively. DETD-35 offers significant potential for advancing research in melanoma treatment strategies.</p>Fórmula:C27H24O6Cor e Forma:SolidPeso molecular:444.48ZSQ836
CAS:<p>ZSQ836 is a dual covalent inhibitor of CDK12/CDK13 with oral bioactivity, displaying an EC50 value of 32 nM against CDK12. This compound can induce cell apoptosis (apoptosis) and demonstrates in vivo anticancer properties. ZSQ836 is applicable for research in ovarian cancer.</p>Fórmula:C27H28AsClN6OS2Cor e Forma:SolidPeso molecular:627.05Ref: TM-T200333
Produto descontinuadoIHMT-MST1-39
CAS:<p>IHMT-MST1-39 is an orally effective MST kinase inhibitor with IC50 values of 42 nM for MST1 and 109 nM for MST2. It activates the AMPK signaling pathway in hepatocytes and inhibits apoptosis in pancreatic β cells. Additionally, IHMT-MST1-39 improves type 1 diabetes in mice induced by Streptozotocin.</p>Fórmula:C20H18F2N6O3SCor e Forma:SolidPeso molecular:460.46Ref: TM-T200512
Produto descontinuadoCyy-272
CAS:<p>Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25, 1.07, and 1.24 μM against JNK1, JNK2, and JNK3, respectively. It exerts anti-inflammatory effects by inhibiting the phosphorylation of JNK, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS). Moreover, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissues caused by high lipid concentrations, further mitigating resultant cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 is utilized in the study of obesity-related myocarditis.</p>Fórmula:C23H23F2N7Cor e Forma:SolidPeso molecular:435.47Ref: TM-T200453
Produto descontinuadoSMIP34
CAS:<p>SMIP34 is an inhibitor of PELP1 that demonstrates the capability to reduce cell viability and colony formation. Additionally, SMIP34 induces cell apoptosis (apoptosis) and causes cell cycle arrest in the S phase. It reduces the expression of PELP1 and exhibits anti-tumor activity. SMIP34 also has potential for research in triple-negative breast cancer (TNBC).</p>Fórmula:C20H15ClFN5O2SCor e Forma:LiquidPeso molecular:443.88CHMFL-48
CAS:<p>CHMFL-48, an orally active inhibitor of BCR-ABL kinase, demonstrates efficacy against both the wild-type (wt) and various imatinib-resistant mutants. It exhibits potent inhibitory activity, with IC 50 values of 1 nM for the ABL wild-type and 0.8 nM for the ABL T315I mutant. CHMFL-48 operates by inhibiting the autophosphorylation of both wild-type and mutant BCR-ABL, affecting downstream signaling mediators including STAT5 and CRKL. This disruption leads to cell cycle arrest and triggers apoptosis. Given its properties, CHMFL-48 is a promising candidate for research on chronic myeloid leukemia (CML).</p>Fórmula:C31H30F3N7OCor e Forma:SolidPeso molecular:573.61
![[D-Leu-4]-OB3](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT72906.webp&w=3840&q=75)
![Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA00I84B.webp&w=3840&q=75)
